PHIL Share Price Performance
€22.70
0.20 (0.89%)
1.3% undervalued intrinsic discount
€23.00
Fair Value
Price €22.70
AnalystConsensusTarget €23.00
AnalystLowTarget €18.00
Fair Value€23.00
Share Pricen/a
Narrative Update • Apr 20
Philogen S.p.A. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
PHIL Community Narratives
AN
Fair Value
·Fair Value €23 1.3% undervalued intrinsic discount
Analysts Maintain €26 Target for Philogen as Buyback and Valuations Remain Stable
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value €18 26.1% overvalued intrinsic discount
Clinical Pipeline And Radiopharmaceutical Expansion Will Pressure Margins And Future Earnings Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Analysts Maintain €26 Target for Philogen as Buyback and Valuations Remain Stable
Key Takeaways Advancing late-stage therapies and strategic pharma partnerships position Philogen for recurring product sales, stronger margins, and reduced funding risk through enhanced cash flow visibility. Alignment with personalized medicine trends and a robust cash position support long-term growth, innovation, and protection of shareholder value amid rising global demand for oncology solutions.Read more
AN
€23
1.3% undervalued intrinsic discount
Fair Value
Revenue
-40.87% p.a.
Profit Margin
13.32%
Future PE
133.42x
Price in 2029
€29.13
Clinical Pipeline And Radiopharmaceutical Expansion Will Pressure Margins And Future Earnings Potential
Catalysts About Philogen Philogen develops targeted biological and small molecule therapies, primarily for oncology and certain inflammatory diseases. What are the underlying business or industry changes driving this perspective?Read more
AN
€18
26.1% overvalued intrinsic discount
Fair Value
Revenue
-11.56% p.a.
Profit Margin
45.27%
Future PE
34.91x
Price in 2029
€22.99
Trending Discussion
Recently Updated Narratives
AN
PHIL: Softer Earnings Outlook And 2026 Board Milestones Will Shape Repricing Potential
Fair Value: €23 1.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Clinical Pipeline And Radiopharmaceutical Expansion Will Pressure Margins And Future Earnings Potential
Fair Value: €18 26.1% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Philogen S.p.A. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Sep 23, 2026
- 5.70
- 87.62%
- 71.83%
- 0.01%
About PHIL
- Founded
- 1996
- Employees
- 214
- CEO
- WebsiteView website
Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company develops Nidlegy which is in Phase III clinical trial for the treatment of advanced melanoma and Phase II clinical trial for the treatment of basal cell carcinoma and cutaneous squamous cell carcinoma; Fibromun which is in Phase III clinical trial for the treatment of soft-tissue sarcoma and Phase II clinical trial for the treatment of glioblastoma; Darleukin which is in Phase II clinical trial for the treatment of non-small cell lung cancer; Dekavil which is in Phase II clinical trial for the treatment of chronic inflammatory disorders; and Dodekin which is in Phase I clinical trial for the treatment of various solid tumors. It is also involved in the development of small molecule products, including OncoFAP which is in Phase I clinical trial for the treatment of solid tumors; OncoACP3 which is in Phase I clinical trial for the treatment of prostate cancer; and OncoCAIX which is in Phase 1 trial for the treatment of renal cell carcinoma and other hypoxic tumors. The company was founded in 1996 and is headquartered in Sovicille, Italy.
